UCAT University Clinical Aptitude Test — VIP Practice Exam
UCAT — The University Clinical Aptitude Test (UCAT) is administered by Pearson VUE on behalf of a consortium of UK, Australian, and New Zealand universities; it comprises five timed sections — Verbal Reasoning (44 questions, 21 min), Decision Making (29 questions, 31 min), Quantitative Reasoning (36 questions, 24 min), Abstract Reasoning (55 questions, 13 min), and Situational Judgement (69 items, 26 min) — for approximately 233 items total; scores are reported on a 300–900 scale per cognitive subtest and in Bands 1–4 for Situational Judgement, with universities setting their own competitive cut-off thresholds rather than a single universal pass mark. The 70% threshold used here is a representative practice standard only.
VERBAL REASONING — Passage 1. Read the following passage and answer the question below. "The emergence of antimicrobial resistance (AMR) poses one of the greatest threats to global public health in the twenty-first century. The World Health Organisation has described AMR as a 'slow-motion pandemic', estimating that by 2050 it could cause more deaths annually than cancer. A significant contributor to AMR is the overuse and misuse of antibiotics in both human medicine and agriculture. Studies indicate that in some countries, up to 50% of antibiotic prescriptions in primary care are inappropriate — prescribed either for viral infections where antibiotics are ineffective, or at incorrect dosages. Stewardship programmes, which provide guidelines for appropriate antibiotic use, have demonstrated success in reducing unnecessary prescribing. However, implementation remains inconsistent, particularly in low- and middle-income countries where access to diagnostics is limited. Vaccines also offer a preventive pathway: by reducing the incidence of bacterial infections, they lessen the demand for antibiotics and thereby reduce selective pressure on bacteria. Research into novel antimicrobial agents is ongoing but has slowed due to economic disincentives — developing a new antibiotic is costly, and its clinical use is deliberately restricted to preserve efficacy, reducing the commercial return for pharmaceutical companies." According to the passage, which of the following is cited as the primary reason pharmaceutical companies have reduced investment in antibiotic research?
Questions 2–31 and full explanations are VIP-exclusive.